The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China-Reference-Cited by-同舟云学术

The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China

Published:2024-09-05 Issue:11 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Cui Hao,Yang Yongpu,Song Liqiang,Yuan Zhen,Sun Linde,Du Jiajun,Lu Yuyuan,Ning Ning,Cui Jianxin,Shi Yan,Chen Lin,Wei Bo

Funder

National Natural Science Foundation of China

Beijing Science and Technology Program

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-024-03802-6.pdf

Reference31 articles.

1. Qi J, Li M, Wang L, Hu Y, Liu W, Long Z et al (2023) National and subnational trends in cancer burden in China, 2005–20: an analysis of national mortality surveillance data. Lancet Public Health 8:e943–e955. https://doi.org/10.1016/S2468-2667(23)00211-6

2. Ji J, Wang R, Shi S, Liu Y, Liu H, Li P, Sheng L, Wu A, Zhou Z, Zhou A, Fang X (2022) National guidelines for diagnosis and treatment of gastric cancer in China. Chin J Cancer Res 34:207–237. https://doi.org/10.21147/j.issn.1000-9604.2022.03.04

3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20. https://doi.org/10.1056/NEJMoa055531

4. Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T et al (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11:6093. https://doi.org/10.1038/s41467-020-19965-6

5. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22(8):1081–1092. https://doi.org/10.1016/S1470-2045(21)00417-4